arrow
D

David C. de Leeuw

amsterdam university medical centers
H指数:13
被引数:576

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy

基于流式细胞术的可测量残留病灶评估在接收非强化化疗的急性髓系白血病患者中的应用

2026-03-190
PREAI
Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemia
2026-03-011
PRE
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

流式细胞术基线可测残留病评估中定量下限作为低水平截断值的预后相关性研究

Leukemia
IF13.4
2025-12-100
OA
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients

高强度治疗患者中急性髓系白血病干细胞定量测定的不同特征。Haematologica

2025-12-012
OA
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee

可测量残留疾病指导下的干预措施在异基因造血细胞移植的急性髓系白血病患者中的应用:欧洲血液与骨髓移植学会实践协调与指南委员会的最佳实践建议

2025-10-270
PRE
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中的计算性微小残留病评估:一项在HOVON-SAKK-132试验中的回顾性验证

Leukemia
IF13.4
2025-09-030
OAAI
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis
2018-12-0118
OAAI